Everest Medicines Appoints Rogers Yongqing Luo as Chief Executive Officer to Lead Next Stage of Company Growth

avatar
by Lindsey Francy Sep 19, 2022 News
Everest Medicines Appoints Rogers Yongqing Luo as Chief Executive Officer to Lead Next Stage of Company Growth

PR NewswirePR Newswire
Sign in to add to watchlist

Everest Medicines is focused on developing and commercializing innovative pharmaceutical products to address critical unmet needs in Asia Pacific markets. Everest's Board of Directors will have an executive director on it.

Mr. Luo brings more than 25 years of experience in the healthcare industry with him to Everest. The amubarvimab/romlusevimab combination, the first COVID-19 neutralizing antibody, was successfully commercialized by Mr. Luo as President and General Manager, Greater China. He was Global Vice President and China General Manager at Gilead Sciences, where he led the clinical development, regulatory approval and successful commercial launch of eight innovative therapies. Several high-profile medicines were successfully launched by Mr. Luo. He was in charge of sales, marketing, government affairs and market access for several multinational pharmaceutical companies and worked for two years at the Swiss headquarters of one of them.

"As Everest Medicines continues to evolve our business strategy and expand our novel product portfolio at a rapid pace, we are thrilled to have Rogers join the Company to lead Everest through its next phase of growth in becoming a fully-integrated biopharma company in China," said Mr. Rogers brings to Everest a unique set of expertise including comprehensive scientific insight, proven outstanding leadership and excellent commercialization capabilities in patient access, and a demonstrated history of successfully advanced early- and late-stage innovative drugs. Everest's new product development and commercial capabilities will be strengthened by Rogers' leadership as we progress towards potential approvals of our anchor product candidates. We look forward to using Rogers' expertise and leadership to grow the business.

I'm very excited to join Everest and I'm looking forward to working with this talented, world-class team of scientists and industry professionals to further the Company's industry leadership. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, said that they aim to execute synergistic business development deals to accelerate their path to become an integrated bio pharma. To create sustained, long-term value for our shareholders, we will continue to invest into our discovery platform to build an innovative therapeutic pipeline for the benefit of patients with unmet needs.

Everest Medicines has something to say about it.

Everest Medicines focuses on developing and commercializing pharmaceutical products that address critical unmet medical needs in Asian markets. Everest Medicines has a track record of high quality clinical development, regulatory affairs, business development and operations in China and with leading global pharmaceutical companies. Many of the first-in-class or best-in-class Molecules built by Everest Medicines are in late-stage clinical development. Immunology, cardio-renal diseases, and infectious diseases are some of the areas of interest for the company. You can find more information on its website.

There are forward-looking statements.

The news release may include descriptions of the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company. Risks and uncertainties, some of which are beyond the control of the Company, are included in the forward-looking statements. Future changes and developments in our business, competitive environment, political, economic, legal and social conditions are some of the factors that may affect the actual results. There is no obligation for the Company or any of its affiliates, directors, officers, advisors or representatives to revise their forward-looking statements after the date of this news release.

rogers-yongqing-luo-as-chief-executive-officer-to-lead-next-stage-of-company

Everest Medicines is the source of this information.

  • Each company's stock has long been a go-to vehicle for investors looking for income. Which is the better telecom stock at the moment? AT&T is in a transition.

  • Desperate times call for desperate measures, and this might be just such a time: persistently high inflation might force the Federal Reserve to resort to the biggest increase in a key U.S. interest rate in more than four decades.

  • Immigration applications can be prepared safely and securely online. Application package assembly services include supporting evidence document translation.

  • It's hard to see the Federal Reserve easing up on its stance on the economy. The first sectors to recover if a bull market returns are fintechs. If you're hoping to take advantage, you might want to consider Affirmholdings, Block, and Mastercard.

  • In early Monday morning trading in Asia, after breaching the support line overnight, the price of Bitcoins fell back below US$20,000. The price of the digital currency fell below the US$20,000 mark.

  • It's easy to make an investment decision when money is at stake. The energy industry has been home to high-yield dividend stocks for years and the current imbalance of global oil and gas supply coupled with rising demand and years of under investment adds a layer of reliability not seen in the energy industry for some time. Three of the most attractive oil and gas companies to consider now are Baker Hughes, DVN, and KMI.

  • There is an easy-to-earn welcome bonus on this award winning cash back card. No fee every year.

  • One of every four tons of copper imported into China is handled by He Jinbi, the most powerful copper trading house in the world.

  • When appropriate, recent actions and grades from TheStreet'sQuant Ratings, we zero in on three names. We will not be weighing in with fundamental analysis, but we hope this piece will give investors a good starting point for further research on the names. TheStreet has a C+ rating on Dollar Tree Inc.

  • The stock market has been a tough place to invest in this year. Market volatility increases due to high inflation and interest rates. Sofi Technologies was a hot stock when it first went public, but now it is feeling the pain.

  • With stock prices falling, investors are able to make more money from investments.

  • Reliability is the most important thing when it comes to dividends. Retirees and other investors rely on dividend stocks to pay them consistently so if you're an income investor you want to make sure you choose stocks that can pay you in good times and bad The list of Dividend Kings, S&P 500 members that have raised their dividends every year for at least 50 years is a good place to start.

  • Two of the biggest tech companies are going through a tough time. Both companies lost a lot of money during the trading week. Facebook is a shadow of what it was a year ago.

  • There is stock from GAP. You can shop now.

  • Being king is good.

  • Investor's Business Daily

    Ahead of its earnings report, sellers have knocked the stock down.

  • The business models of these two companies are very similar.

  • Home equity and cash out refinance rates are the best today. You can view rates and calculate payment. Ten, fifteen, twenty, thirty year terms. You can view rates now.

  • We are going to look at the 10 blue chip stocks to buy now according to billionaire Ray Dalio. You can skip our analysis of Ray Dalio's profile, investment strategy, and 13F holdings by going directly to the 5 blue chip stocks to buy now according to billionaire Ray Dalio. There with.

  • It's possible to earn a lifetime of passive income by buying high-quality dividends. Many companies have a long history of growing their payouts and this will allow you to cover more of your expenses with dividends. There are three top-tier dividend stocks for passive income.

  • The bear market and stock splits are two of the themes that will define the stock market in the year 2022. The technology sector has been disproportionately affected by both, with some of the largest tech companies in the U.S. opting for stock splits to lower their share prices. In the last four months, Palo Alto Networks, Shopify, and TSLA have all had stock splits.

  • The new system keeps an eye on you around the clock. Dispatch is under $1 a day. Everything can be seen from your app.

  • If you want to attract people, you need to look at two giant yields and one that might not be worth the risk.

  • The quarter has not been the best for Novavax, Inc.

  • 401(k) Savers who want to enjoy tax benefits on their 401(k) should look at a mega back door hirsut. You can learn how a mega back door can work.